John H. Weiland Sells 14,091 Shares of C.R. Bard, Inc. (BCR) Stock
C.R. Bard, Inc. (NYSE:BCR) Vice Chairman John H. Weiland sold 14,091 shares of the stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $240.49, for a total value of $3,388,744.59. Following the completion of the transaction, the insider now directly owns 68,978 shares in the company, valued at approximately $16,588,519.22. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of C.R. Bard, Inc. (NYSE:BCR) opened at 241.79 on Friday. The company has a market cap of $17.42 billion, a PE ratio of 34.39 and a beta of 0.63. C.R. Bard, Inc. has a 52-week low of $185.72 and a 52-week high of $242.50. The company has a 50 day moving average of $234.21 and a 200-day moving average of $222.72.
C.R. Bard (NYSE:BCR) last posted its earnings results on Thursday, January 26th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.74 by $0.03. The firm had revenue of $967.10 million for the quarter, compared to analysts’ expectations of $956.12 million. C.R. Bard had a net margin of 14.31% and a return on equity of 48.48%. The company’s revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.43 earnings per share. Analysts forecast that C.R. Bard, Inc. will post $11.64 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, February 3rd. Shareholders of record on Monday, January 23rd were paid a dividend of $0.26 per share. The ex-dividend date was Thursday, January 19th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.43%. C.R. Bard’s payout ratio is presently 14.77%.
“John H. Weiland Sells 14,091 Shares of C.R. Bard, Inc. (BCR) Stock” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this story can be viewed at http://www.dailypolitical.com/2017/02/17/john-h-weiland-sells-14091-shares-of-c-r-bard-inc-bcr-stock.html.
A number of research analysts have recently weighed in on BCR shares. BMO Capital Markets raised C.R. Bard from a “market perform” rating to an “outperform” rating and set a $240.00 price target on the stock in a research note on Wednesday, October 26th. They noted that the move was a valuation call. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $241.00 price target on the stock in a research note on Thursday, October 27th. Morgan Stanley raised C.R. Bard from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $240.00 to $260.00 in a research note on Tuesday, January 3rd. Raymond James Financial, Inc. raised C.R. Bard from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $250.00 to $265.00 in a research note on Thursday, January 5th. Finally, JMP Securities increased their price target on C.R. Bard from $240.00 to $255.00 in a research note on Friday, January 27th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $244.14.
Several hedge funds have recently bought and sold shares of BCR. Alyeska Investment Group L.P. bought a new stake in C.R. Bard during the fourth quarter worth $85,208,000. APG Asset Management N.V. boosted its stake in C.R. Bard by 138.0% in the third quarter. APG Asset Management N.V. now owns 592,362 shares of the company’s stock worth $132,855,000 after buying an additional 343,449 shares during the last quarter. BlackRock Fund Advisors boosted its stake in C.R. Bard by 15.3% in the second quarter. BlackRock Fund Advisors now owns 2,175,495 shares of the company’s stock worth $511,589,000 after buying an additional 288,839 shares during the last quarter. Standard Life Investments LTD boosted its stake in C.R. Bard by 27.4% in the third quarter. Standard Life Investments LTD now owns 1,309,071 shares of the company’s stock worth $293,565,000 after buying an additional 281,458 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in C.R. Bard by 303.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 294,872 shares of the company’s stock worth $69,342,000 after buying an additional 221,741 shares during the last quarter. 86.89% of the stock is currently owned by hedge funds and other institutional investors.
About C.R. Bard
C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.